Cargando…

Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer

Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient response to chemotherapy. However, the cutoff value of the half-maximal inhibition concentration (IC(50)) for PDTO drug sensitivity has not been validated with clinical cohort data. We established PDTOs and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yuting, Wang, Ting, Hu, Yaowen, Ji, Hongli, Yan, Botao, Hu, Xiarong, Zeng, Yunli, Hao, Yifan, Xue, Weisong, Chen, Zexin, Lan, Jianqiang, Wang, Yanan, Deng, Haijun, Deng, Chuxia, Wu, Xiufeng, Yan, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329174/
https://www.ncbi.nlm.nih.gov/pubmed/37426352
http://dx.doi.org/10.1016/j.isci.2023.107116
_version_ 1785069965108314112
author Tang, Yuting
Wang, Ting
Hu, Yaowen
Ji, Hongli
Yan, Botao
Hu, Xiarong
Zeng, Yunli
Hao, Yifan
Xue, Weisong
Chen, Zexin
Lan, Jianqiang
Wang, Yanan
Deng, Haijun
Deng, Chuxia
Wu, Xiufeng
Yan, Jun
author_facet Tang, Yuting
Wang, Ting
Hu, Yaowen
Ji, Hongli
Yan, Botao
Hu, Xiarong
Zeng, Yunli
Hao, Yifan
Xue, Weisong
Chen, Zexin
Lan, Jianqiang
Wang, Yanan
Deng, Haijun
Deng, Chuxia
Wu, Xiufeng
Yan, Jun
author_sort Tang, Yuting
collection PubMed
description Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient response to chemotherapy. However, the cutoff value of the half-maximal inhibition concentration (IC(50)) for PDTO drug sensitivity has not been validated with clinical cohort data. We established PDTOs and performed a drug test in 277 samples from 242 CRC patients who received FOLFOX or XELOX chemotherapy. After follow-up and comparison of the PDTO drug test and final clinical outcome results, the optimal IC(50) cutoff value for PDTO drug sensitivity was 43.26 μmol/L. This PDTO drug test-defined cutoff value could predict patient response with 75.36% sensitivity, 74.68% specificity, and 75% accuracy. Moreover, this value distinguished groups of patients with significant differences in survival benefit. Our study is the first to define the IC(50) cutoff value for the PDTO drug test to effectively distinguish CRC patients with chemosensitivity or nonsensitivity and predict survival benefits.
format Online
Article
Text
id pubmed-10329174
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103291742023-07-09 Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer Tang, Yuting Wang, Ting Hu, Yaowen Ji, Hongli Yan, Botao Hu, Xiarong Zeng, Yunli Hao, Yifan Xue, Weisong Chen, Zexin Lan, Jianqiang Wang, Yanan Deng, Haijun Deng, Chuxia Wu, Xiufeng Yan, Jun iScience Article Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient response to chemotherapy. However, the cutoff value of the half-maximal inhibition concentration (IC(50)) for PDTO drug sensitivity has not been validated with clinical cohort data. We established PDTOs and performed a drug test in 277 samples from 242 CRC patients who received FOLFOX or XELOX chemotherapy. After follow-up and comparison of the PDTO drug test and final clinical outcome results, the optimal IC(50) cutoff value for PDTO drug sensitivity was 43.26 μmol/L. This PDTO drug test-defined cutoff value could predict patient response with 75.36% sensitivity, 74.68% specificity, and 75% accuracy. Moreover, this value distinguished groups of patients with significant differences in survival benefit. Our study is the first to define the IC(50) cutoff value for the PDTO drug test to effectively distinguish CRC patients with chemosensitivity or nonsensitivity and predict survival benefits. Elsevier 2023-06-13 /pmc/articles/PMC10329174/ /pubmed/37426352 http://dx.doi.org/10.1016/j.isci.2023.107116 Text en © 2023. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Tang, Yuting
Wang, Ting
Hu, Yaowen
Ji, Hongli
Yan, Botao
Hu, Xiarong
Zeng, Yunli
Hao, Yifan
Xue, Weisong
Chen, Zexin
Lan, Jianqiang
Wang, Yanan
Deng, Haijun
Deng, Chuxia
Wu, Xiufeng
Yan, Jun
Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer
title Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer
title_full Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer
title_fullStr Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer
title_full_unstemmed Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer
title_short Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer
title_sort cutoff value of ic(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329174/
https://www.ncbi.nlm.nih.gov/pubmed/37426352
http://dx.doi.org/10.1016/j.isci.2023.107116
work_keys_str_mv AT tangyuting cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT wangting cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT huyaowen cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT jihongli cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT yanbotao cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT huxiarong cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT zengyunli cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT haoyifan cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT xueweisong cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT chenzexin cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT lanjianqiang cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT wangyanan cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT denghaijun cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT dengchuxia cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT wuxiufeng cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer
AT yanjun cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer